Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Theravex Oral and Theravex Tissue Care Plus to improve healing after mucogingival surgery

Official title: Clinical Study on the Efficacy of Theravex Oral and Theravex Tissue Care Plus in Periodontal Surgery" Modified Free Gingival Graft for the Treatment of RT1-RT2: A Randomized Clinical Trial

Run by Universidad Complutense de Madrid · NCT07430670 · Data updated 2026-11-12

We will test if applying Theravex Tissue Care Plus during a modified free gingival graft and rinsing with Theravex Oral afterward helps adults with lower-front gum recession heal faster and get better root coverage than a saline placebo.

More Gingival Recession trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment30 (estimated)
SponsorUniversidad Complutense de Madrid
Academic / other
Locations1 site (Madrid, Madrid)
StatusRecruiting
StartedFebruary 17, 2026
Main results expectedJuly 6, 2027
Study endsJuly 6, 2027
Registry record updatedFebruary 24, 2026
Trial IDNCT07430670 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Healthy adults (≥18) with at least one RT1–RT2 recession on a mandibular incisor, shallow probing depths (≤3 mm), low plaque levels, and willingness to attend scheduled follow-ups are the ideal candidates.

Probably not a fit

Smokers of ≥10 cigarettes/day, pregnant patients, those with uncontrolled systemic disease, untreated parafunctional habits, or incompatible dental restorations are unlikely to qualify or benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind trial at the Complutense University of Madrid enrolls adults with RT1–RT2 gingival recessions on mandibular incisors who require a modified free gingival graft (M-FGG). Participants are randomly assigned to receive either Theravex Tissue Care Plus applied to the graft and recipient site plus 14 days of twice-daily Theravex Oral rinses, or the same surgical protocol with a blinded saline placebo. The primary outcome is reduction in recession depth at 12 months, and secondary outcomes include keratinized tissue width, soft tissue thickness, volumetric 3D changes, tissue color integration by spectrophotometry, vascularization by Laser Speckle Contrast Imaging, and postoperative pain. Follow-up includes clinical exams and digital imaging over a one-year period.

Why it matters

Potential benefit: If successful, the treatment could produce better root coverage, increased tissue thickness and color match, and less postoperative pain after gum graft surgery.

How similar studies have gone: Preclinical data for the Bone Bioactive Liquid show promising effects on hard and soft tissue regeneration, but clinical evidence for these specific Theravex solutions in mucogingival surgery is limited and the approach is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Healthy patients aged ≥ 18 years.
* Patients with at least one mandibular incisor presenting a gingival recession RT1-RT2 and requiring a free gingival graft.
* Periodontal health in either an intact or reduced periodontium (Chapple et al., 2018) with a plaque index ≤ 20% (O'Leary et al., 1972).
* Initial probing depth ≤ 3 mm in the treated teeth.
* No dental mobility (grade ≤ 1) in the treated teeth.
* Well-defined CEJ
* Agreement to take part in this study (signed informed consent).

Exclusion Criteria:

* Smokers ≥10 cigarettes/day.
* Patients treated with Theravex \[IS1.1\]\[ma1.2\]previously.
* Untreated parafunctional habits.
* Restorations that cannot be removed for proper treatment.
* Pregnant patients or cases with uncertain pregnancy status (self-reported).
* Patients with uncontrolled systemic diseases, neurological, psychiatric disorders, or other known conditions capable of influencing the results of the study.
* Patients not attending follow-ups or not signing informed consent.

Where it's running

  • Complutense University of Madrid
    Madrid, Madrid, Spain
    Recruiting

Study contacts

  • Principal investigator: Mariano Sanz Alonso, DMD, MD, PHD — Universidad Complutense de Madrid
  • Study coordinator: Mariano Sanz Alonso, DMD, MD, PHD
  • Email: marsan@ucm.es
  • Phone: 913942021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.